- Autolus Therapeutics plc AUTL has granted Moderna Inc MRNA an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.
- Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments.
- In addition, Autolus would be entitled to receive royalties on net sales.
- Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
